TY - JOUR
T1 - Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome — Experience in 300 patients
AU - Gonwa, Thomas A.
AU - Morris, Christine A.
AU - Goldstein, Robert M.
AU - Husberg, Bo S.
AU - Klintmalm, Goran B.
PY - 1991/2
Y1 - 1991/2
N2 - We have retrospectively reviewed the first 308 patients undergoing orthotopic liver transplantation (OLTX) at our institution to determine the following: 1) To what extent does renal function deteriorate postop- eratively? 2) To what extent does renal function recover after OLTX for hepatorenal syndrome (HRS)? 3) What is the survival rate of patients with HRS compared with those without HRS? In non-HRS patients, GFR declined from 97.1±2.9 cc/ min to 56.6±2.4 cc/min at 6 weeks postoperative, 62.6± 2.6 cc/min at 1 year, and 58.3±3.5 cc/min at 2 years. In HRS patients, GFR increased from 19.9±3.6 cc/min to 32.5±3.1 cc/min at 6 weeks, 45.9±5.5 cc/min at 1 year, and 37.9±5.9 cc/min at 2 years. Dosages of cyclosporine were comparable in both groups. There was no difference in perioperative (90-day) mortality. One- and 2- year actuarial survival rates in the non-HRS patients were 87.2% and 82.1%, respectively. The actuarial 1- and 2-year survival rate for the HRS patients was 76.6% (P=NS). Ten percent of HRS patients developed ESRD posttransplant compared with 0.8% of non-HRS patients (P<0.005). We conclude that patients with HRS can safely undergo OLTX with acceptable perioperative mortality and good long-term survival. Most HRS patients have return of acceptable renal function. Patients without HRS have a severe decline in GFR posttransplant, which is stable up to 3 years posttransplant.
AB - We have retrospectively reviewed the first 308 patients undergoing orthotopic liver transplantation (OLTX) at our institution to determine the following: 1) To what extent does renal function deteriorate postop- eratively? 2) To what extent does renal function recover after OLTX for hepatorenal syndrome (HRS)? 3) What is the survival rate of patients with HRS compared with those without HRS? In non-HRS patients, GFR declined from 97.1±2.9 cc/ min to 56.6±2.4 cc/min at 6 weeks postoperative, 62.6± 2.6 cc/min at 1 year, and 58.3±3.5 cc/min at 2 years. In HRS patients, GFR increased from 19.9±3.6 cc/min to 32.5±3.1 cc/min at 6 weeks, 45.9±5.5 cc/min at 1 year, and 37.9±5.9 cc/min at 2 years. Dosages of cyclosporine were comparable in both groups. There was no difference in perioperative (90-day) mortality. One- and 2- year actuarial survival rates in the non-HRS patients were 87.2% and 82.1%, respectively. The actuarial 1- and 2-year survival rate for the HRS patients was 76.6% (P=NS). Ten percent of HRS patients developed ESRD posttransplant compared with 0.8% of non-HRS patients (P<0.005). We conclude that patients with HRS can safely undergo OLTX with acceptable perioperative mortality and good long-term survival. Most HRS patients have return of acceptable renal function. Patients without HRS have a severe decline in GFR posttransplant, which is stable up to 3 years posttransplant.
UR - http://www.scopus.com/inward/record.url?scp=0026096518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026096518&partnerID=8YFLogxK
U2 - 10.1097/00007890-199102000-00030
DO - 10.1097/00007890-199102000-00030
M3 - Article
C2 - 1994538
AN - SCOPUS:0026096518
SN - 0041-1337
VL - 51
SP - 428
EP - 430
JO - Transplantation
JF - Transplantation
IS - 2
ER -